Flunisolide

Sold as Nasalide, Aerobid, Nasarel, Aerospan Hfa. Every FDA application for this active ingredient: 4 branded and 4 generic.

As of Nov 13, 2026, FDA lists 8 applications for Flunisolide (sold as Nasalide, Aerobid, Nasarel and others), first approved Sep 24, 1981, with 2 new uses approved and 0 published complete response letters.

First approved: Sep 24, 1981
Applications: 8
New uses approved: 2
Complete response letters: 0
Medicare spending, 2025: $2.4M

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name

Product	Part	Spending, 2025	Change	Beneficiaries
Flunisolide	Part D	$2.4M	-12%	16,844

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Sep 24, 1981	NasalideNDA 18148 · New molecular entity	Ivax Res	31	Discontinued
Aug 17, 1984	AerobidNDA 18340 · New dosage form	Roche Palo	10	Discontinued
Mar 8, 1995	NasarelNDA 20409 · New dosage form	Teva Branded Pharm	10	Discontinued
Feb 20, 2002	FlunisolideANDA 74805	Bausch	2	Marketed
Jan 27, 2006	Aerospan HfaNDA 21247 · New dosage form	Pharmobedient	11	Discontinued
Aug 3, 2006	FlunisolideANDA 77704	Rising	0	Marketed
Aug 9, 2007	FlunisolideANDA 77436	Apotex	0	Discontinued
Jun 16, 2022	FlunisolideANDA 207802	Riconpharma LLC	0	Marketed

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number. Drugs@FDA